



TISSUEGENE CHOOSES AT-GC BIOPHARM'S QUALITY BY DESIGN MANUFACTURING SOLUTION FOR THEIR PRODUCTS

Clarksburg, MD.-- July 20, 2005—AT-GC BioPharm announced today that TissueGene will be using AT-GC BioPharm's market-leading Quality By Design manufacturing solution to produce their plasmid vectors. TissueGene is the leading biopharmaceutical company developing treatment and regeneration of damaged cartilage and bones and nerves.

"We are delighted to be working with TissueGene and continuing to expand and strengthen our relationship with the TissueGene management," said Arkesh Mehta, Chief Executive Officer of the AT-GC BioPharm. "The implementation of the AT-GC BioPharm Signature Manufacturing solution will provide TissueGene with a clean and consistent quality of their product. This will also meet their needs as their requirements change and grow, with the continuing demands of additional capacity and enhanced and more sophisticated biopharmaceutical products development. Our solution will enable them to ensure the highest levels of product quality."

AT-GC BioPharm solutions are specifically designed for biopharmaceutical process management and have been successfully deployed for biopharmaceutical product manufacturing. These technologies include its proprietary electronic eye, signature manufacturing, non-invasive real-time sensors and high throughput process development technologies. More information on AT-GC BioPharm's complete line of process development and manufacturing solutions can be found at www.AT-GC BioPharm.com.

[ABOUT TISSUEGENE](#)

TissueGene, Inc. is a Maryland-based company focused on developing a proprietary suite of regenerative orthopedic therapeutic products directed to the treatment and regeneration of damaged cartilage, bones, and nerves. The company's core technology employs a form of cell-mediated therapy to deliver therapeutic proteins to damaged tissue, which initiates rapid and permanent repair of injured tissue without the need for surgery. TissueGene has successfully advanced the scientific and regulatory aspects of the first product in its pipeline, a product for the regeneration of cartilage, to the stage of entering Phase I. The first indication for this product will be focused on patients with osteoarthritis of the knee.

To find out more about TissueGene, visit www.TissueGene.com



ABOUT AT-GC BIOPHARM

AT-GC BioPharm is an emerging biopharmaceutical company dedicated to the discovery and development of innovative technologies for rapidly advancing knowledge based manufacturing of biopharmaceutical products for consistent quality. AT-GC BioPharm is uniquely able to develop innovative technologies by accelerating and enhancing the process development skills and experience of proven drug manufacturing processes with world-class, proprietary process development technologies developed in collaboration with their partners. AT-GC BioPharm has established an exclusive worldwide strategic alliance with Avanti Therapeutics to develop and commercialize novel drug compounds for the treatment of infectious diseases and cancer. The company operates globally with headquarters in Clarksburg, Maryland, USA, and major offices in Baltimore, MD., Oxford, UK, and Mumbai, India. To learn why more and more biopharmaceutical companies trust AT-GC BioPharm as their preferred process development partner, visit www.at-gc.com.

For additional information, please visit the company website, www.biopharm.at-gc.com

AT-GC BioPharm. Contact:

Jenny Smith
Communications
jenny@at-gc.com
301-540-5474

TissueGene Inc. Contact:

J. Kelly Ganjei
Dir. Business Development
contact@TissueGene.com
301-921-6002